Skip to content
Peptide Atlas
All peptides

Alpha-MSH

Tier 2 · Preclinical
Also known as Alpha-melanocyte-stimulating hormone · Melanotropin · Alpha-MSH peptide

Human randomized controlled trial evidence exists for the α-MSH analogue afamelanotide (subcutaneous implants) in erythropoietic protoporphyria1, and FDA-approved melanocortin analogues (afamelanotide, setmelanotide, bremelanotide) are documented. Native α-MSH glucose-tolerance work is largely preclinical/animal with early small human studies (NCT06293664, ISRCTN26265036). Much of the receptor-affinity, half-life, and molecular characterization comes from lower-tier database/commercial sources and should be read as reference/theoretical. Tumor-immunology, osteogenic, and Tourette's findings are animal, in-vitro, or single small-cohort observations.

Half-life
~0.25 h
Routes
Subcutaneous injection · Subcutaneous implant · Intravenous (dissolved in saline/albumin)
Goals
Skin pigmentation / photoprotection · Anti-inflammatory · Metabolic / glucose regulation · Immune modulation · Sexual function
Cost / mg
Not recorded

How it works

Alpha-MSH is a small, naturally occurring hormone (a 13-amino-acid peptide) that the body makes from a larger precursor protein called POMC. It is produced by skin cells after sun exposure and by the brain/pituitary. It works by switching on melanocortin receptors (MC1R, MC3R, MC4R, MC5R), which are found on many cell types. Through these receptors it drives skin tanning (melanin production), calms inflammation, dampens appetite (promotes feeling full), and influences glucose handling in muscle, immune activity, and sexual behavior. It binds MC1R most strongly, which is why pigment and anti-inflammatory effects are prominent.

Overview

Overview

Alpha-MSH (alpha-melanocyte-stimulating hormone, melanotropin) is a 13-amino-acid endogenous neuropeptide of the melanocortin family. Its sequence is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, with N-terminal acetylation and C-terminal amidation that are critical for full biological activity and stability. It has a molecular weight of ~1,664.88 Da (C77H109N21O19S; CAS 581-05-5; PubChem CID 16162729).

Origin and Biosynthesis

α-MSH is derived from the precursor pro-opiomelanocortin (POMC), a 241-amino-acid polypeptide, via tissue-specific sequential cleavage by prohormone convertases PC1/3 and PC2, trimming by carboxypeptidase E, and acetylation by N-acetyltransferase. The POMC gene (chromosome 2p23.3) is expressed in anterior pituitary corticotrophs, intermediate-lobe melanotrophs, and hypothalamic arcuate nucleus and brainstem (nucleus tractus solitarius) neurons. Notably, ACTH contains the complete α-MSH sequence within its first 13 amino acids. The intermediate lobe of the pituitary is thought to be a primary source; the human fetal intermediate lobe contains high concentrations while the adult human pituitary is reported to be devoid of the peptide. In skin, melanocytes and keratinocytes secrete α-MSH after ultraviolet exposure, making it the principal driver of melanin synthesis and tanning.

Receptor Pharmacology

α-MSH agonizes four of the five melanocortin receptors with varying affinity — MC1R (Ki ≈ 0.23 nM), MC3R (Ki ≈ 31.5 nM), MC4R (Ki ≈ 900 nM), and MC5R (Ki ≈ 7,160 nM). The broader melanocortin system comprises the melanocortin peptides, five receptors, and two endogenous antagonists.

  • MC1R (melanocytes): signals via adenylyl cyclase/cAMP/PKA to upregulate melanogenic enzyme genes and to control DNA-damage repair, reactive-oxygen-species reduction, and cell proliferation.
  • MC4R (hypothalamus): satiety signaling; α-MSH is an anorexigenic peptide central to metabolic regulation.
  • MC5R (skeletal muscle): a role in glucose uptake and disposal.

Physiologic Roles

Reported roles span appetite regulation, immune modulation, anti-inflammatory and antipyretic signaling, neuroprotection, cardiovascular function, antimicrobial defense, energy homeostasis, exocrine secretion, and sexual behavior. α-MSH suppresses NF-κB (preserving IκBα), lowering TNF-α, IL-1β, IL-6, and IL-8, and modulates proinflammatory cytokines both peripherally and centrally. The C-terminal [11-13] fragment (KPV) retains anti-inflammatory and antimicrobial activity, and direct antimicrobial activity against fungal and bacterial pathogens has been reported. In rats, α-MSH interacts with the magnocellular oxytocin system in the supraoptic nucleus, inhibiting feeding and stimulating sexual behavior.

Metabolic / Glucose Findings

As an MC5R agonist in human skeletal muscle, α-MSH has been shown in mouse studies to improve glucose clearance by promoting muscle glucose uptake, and to improve glucose tolerance in healthy humans. A small double-blinded, randomized, placebo-controlled crossover study in Type 2 Diabetes (NCT06293664, estimated enrollment 13) and a study in 15 healthy volunteers (ISRCTN26265036) are investigating these effects; these remain early-stage and preclinical-anchored.

Therapeutic Analogues

Because native α-MSH breaks down in minutes and activates many receptors at once, it was never developed as a drug in its native form. Engineered analogues instead dominate clinical use, and every marketed or developmental melanocortin drug traces its lineage to α-MSH:

  • Afamelanotide — a superpotent MC1R agonist, FDA-approved in 2019 for erythropoietic protoporphyria. In randomized controlled trials it reduced pain and improved quality of life; in the U.S. study (94 patients, 3 implants over 270 days) median pain-free time was 69.4 vs 40.8 hours (P=0.04), and in the EU study (74 patients, 5 implants over 180 days) 6.0 vs 0.8 hours (P=0.005) with fewer phototoxic reactions. It was given as subcutaneous implants containing 16 mg every 60 days.
  • Setmelanotide — a selective MC4R agonist approved in 2020 for rare genetic obesity disorders.
  • Bremelanotide (PT-141) — acting on MC3R/MC4R, approved in 2019 for hypoactive sexual desire disorder in premenopausal women.
  • PL-8177 — a further synthetic effort to harness α-MSH biology with better stability and selectivity.

Research Frontiers

  • Melanoma (dual, contested role): A large body of evidence supports α-MSH/MC1R in preventing melanoma development via melanogenesis and DNA-damage repair. Conversely, MC1R and α-MSH are reported overexpressed in metastatic melanoma (enhanced by BRAF inhibition), potentially promoting immune escape and therapy resistance, positioning MC1R as an anti-cancer target. MC1R overexpression also makes α-MSH analogues promising for melanoma imaging and radionuclide therapy (e.g., cyclic analogues labeled with beta/alpha emitters showed efficacy in the B16 mouse model; [At]NpG-GGN4c inhibited B16F10 xenograft growth dose-dependently without body-weight loss).
  • Tumor immunosuppression: In mice, tumor-induced pituitary α-MSH acted via MC5R on bone-marrow progenitors to promote myelopoiesis and immunosuppression; an MC5R antagonist boosted antitumor immunity and anti-PD-1 therapy, and serum α-MSH correlated with circulating myeloid-derived suppressor cells in cancer patients.
  • Fibrosis: Anti-inflammatory and antifibrotic actions suggest melanocortin agonists might favorably affect fibrosis.
  • Bone: In vitro, α-MSH promoted osteoblast (MC3T3-E1) differentiation and mineralization via MC1R and ERK1/2, suggesting a theoretical target for osteoporosis/bone defects.
  • Neurology: High plasma α-MSH was detected in three unmedicated Tourette's syndrome patients, suggesting a possible link to its pathophysiology.

What the research shows

122 findings extracted from the 21 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 5 human trial findings, 6 human study findings, 8 animal findings, 3 expert opinion findings and 1 theoretical finding.

  • human trialAfamelanotide decreases pain and improves quality of life in erythropoietic protoporphyria patients1

  • human trialIn the U.S. study, the duration of pain-free time after 6 months was longer in the afamelanotide group (median, 69.4 hours, vs. 40.8 hours in the placebo group; P=0.04)1

  • human trialIn the European Union study, the duration of pain-free time after 9 months was longer in the afamelanotide group than in the placebo group (median, 6.0 hours vs. 0.8 hours; P=0.005)1

  • human trialIn the European Union study, the number of phototoxic reactions was lower in the afamelanotide group (77 vs. 146, P=0.04)1

  • human trialQuality of life improved with afamelanotide therapy in both trials1

  • human studyResearch has demonstrated that α-MSH improves glucose tolerance in healthy humans by promoting glucose uptake in skeletal muscle cells5

  • human studyIn metastatic melanoma both MC1R and α-MSH have been reported to be overexpressed at levels much higher than normal cells6

  • human studySerum α-MSH concentration was elevated and correlated with circulating myeloid-derived suppressor cells in cancer patients7

Show 15 more findings

  • human studyAfter alpha-MSH use was discontinued, the nevi progressively lightened and lost their growth features8

  • human studyHigh plasma alpha-MSH concentrations were detected in all three unmedicated TS patients (aged 12 to 69)9

  • human studyIn metastatic melanoma both MC1R and α-MSH have been reported to be overexpressed at levels much higher than normal cells14

  • animalIn animals, infusion of alpha-MSH increases glucose clearance by promoting its uptake in skeletal muscle, thus lowering circulating blood sugar2

  • animalPre-clinical studies in mice have shown improved glucose clearance with α-MSH infusion, particularly in skeletal muscle5

  • animalMC5R peptide antagonist boosted antitumor immunity and anti-programmed cell death protein 1 (anti-PD-1) immunotherapy7

  • animalCyclic α-MSH analogues labeled with beta and alpha emitting radionuclides demonstrated melanoma therapeutic efficacy in the B16 melanoma mouse model10

  • animal[At]NpG-GGN4c exhibited a dose-dependent inhibitory effect on B16F10 xenograft growth without apparent body weight loss13

  • animalA large body of evidence supports α-MSH in preventing melanoma development14

  • animalTargeted therapy (e.g. BRAF inhibition in BRAF mutant tumours) has been shown to enhance MC1R and α-MSH overexpression phenomenon14

  • animalalpha-MSH and oxytocin both inhibit feeding behaviour and stimulate sexual behaviour in rats18

  • expert opinionα-MSH has anti-inflammatory effects3

  • expert opinionα-MSH has antifibrotic actions3

  • expert opinionThere have been recent reports about the direct antimicrobial activity of α-MSH against various microbes belonging to both fungal and bacterial pathogens16

  • theoreticalSynthetic alpha-melanocyte-stimulating hormone (alpha-MSH) peptides may have protective effects against the development of melanoma because of their melanogenic activity8

How it works

Based on 1 human trial finding, 6 human study findings, 11 animal findings, 21 in vitro findings, 21 expert opinion findings and 5 theoretical findings.

  • human trialAfamelanotide is an α-melanocyte–stimulating hormone analogue1

  • human studyα-MSH is a 13 amino acid neuropeptide secreted by melanocytes and keratinocytes after ultraviolet light exposure and it is responsible of the melanin synthesis, being the main actor of skin pigmentation6

  • human studyα-MSH and analogues have anti-inflammatory and anti-microbial properties, activating melanocortin receptors (MCR) signaling6

  • human studySynthetic alpha-MSH peptides can drive proliferation of neoplastic melanocytic cells in predisposed patients8

  • human studyThe intermediate lobe of the human fetus contains high concentrations of alpha-MSH9

  • human studyThe human adult pituitary is devoid of the peptide9

  • human studyAbnormalities in alpha-MSH may be linked to delay in neurodevelopmental maturation9

  • animalAlpha-MSH acts directly on skeletal muscle to increase glucose uptake2

Show 57 more findings

  • animalSubcutaneous implantation of tumors induced hypothalamus activation and pituitary α-melanocyte-stimulating hormone (α-MSH) production in mice7

  • animalα-MSH acted on bone marrow progenitors to promote myelopoiesis, myeloid cell accumulation, immunosuppression, and tumor growth through its melanocortin receptor MC5R7

  • animalAlpha-melanocyte stimulating hormone (α-MSH) peptide analogs show high affinities to MC1Rs13

  • animalThe D-Glu-D-Arg linker was identified as the optimal hydrophilic linker because of its high affinity for MC1R and good biodistribution profile, especially with low accumulation in the liver and intestine13

  • animalα-MSH downstream signalling may promote immune escape and cancer resistance to therapy14

  • animalalpha-MSH induces the release of oxytocin from the dendrites of magnocellular neurones18

  • animalalpha-MSH inhibits the secretion of oxytocin from nerve terminals in the posterior pituitary18

  • animalalpha-MSH interacts with the magnocellular oxytocin system in the supraoptic nucleus18

  • animalmagnocellular neurones can differentially regulate peptide release from dendrites and axons18

  • animalmagnocellular neurones are a major source of central oxytocin release and substrate of oxytocin-mediated behaviours18

  • in vitroα-MSH binds to four out of five MCR subtypes (MC1R, MC3R, MC4R, MC5R), regulating several downstream cascades in different cell types6

  • in vitroIn melanocytes MC1R is highly expressed and the binding of α-MSH promotes the expression of melanogenesis enzyme genes via Adenylyl Cyclase (AC)/cyclic AMP (cAMP)/Protein Kinase A (PKA) pathway6

  • in vitroThe α-MSH/MC1R axis controls a plethora of important processes such as DNA damage repair, reduction of free radical production and cell proliferation among others6

  • in vitroα-MSH is a member of the melanocortin family with important biological functions in diverse cells and tissues15

  • in vitroExpression of the α-MSH membrane receptor MC1R increased distinctively during osteogenic differentiation from 3, 7 to 14 days15

  • in vitroMC2R, MC3R, or MC4R did not increase distinctively during osteogenic differentiation15

  • in vitroTreatment with α-MSH promoted the differentiation and mineralization of MC3T3-E1 cells by increasing the activity of ALP15

  • in vitroα-MSH enhanced Alizarin Red S staining in osteoblast cells15

  • in vitroα-MSH stimulated the expression of osteogenic genes including ALP1, osteocalcin (Bglap2), and osterix (Sp7)15

  • in vitroα-MSH increased the expression of Runx-2, a master transcriptional factor of osteogenic differentiation15

  • in vitroActivation of ERK1/2 was involved in α-MSH promotion of osteoblast differentiation and mineralization15

  • in vitroThe effects of α-MSH on differentiation and mineralization of osteoblast cells are mediated by MC1R15

  • in vitroMelanocortin-1 (MC1) receptor is over-expressed on the surface of melanoma cells17

  • in vitroAlpha-melanocyte stimulating hormone (alpha-MSH) peptide analogues can specifically bind MC1 receptors with nanomolar binding affinities17

  • in vitroAlpha-MSH is a neuroimmunomodulatory peptide involved in the control of host responses19

  • in vitroAlpha-MSH modulates the production and action of proinflammatory cytokines in inflammatory cells in the periphery and within the central nervous system19

  • in vitroAlpha-MSH acts via endogenous alpha-MSH (melanocortin) receptors19

  • in vitroAlpha-MSH inhibits activation of NF-kappa B through preservation of I kappa B alpha19

  • in vitroCells transfected with alpha-MSH plasmid vector are resistant to challenge with bacterial lipopolysaccharide19

  • in vitroAlpha-MSH acts on central melanocortin receptors to modulate inflammation in the periphery19

  • in vitroAlpha-MSH fragment [11-13] KPV modulates inflammation via direct actions on peripheral host cells, actions on inflammatory cells within the brain, and descending neural anti-inflammatory pathways19

  • expert opinionAlpha-melanocyte stimulatory hormone (alpha-MSH) is a hormone that is produced by the brain and released into the bloodstream2

  • expert opinionAlpha-MSH has multiple functions in the body, such as reducing inflammation, promoting skin pigmentation and controlling energy balance2

  • expert opinionThe melanocortin system encompasses melanocortin peptides, five receptors, and two endogenous antagonists3

  • expert opinionα-MSH has physiologic roles in sexual activity, exocrine secretion, and energy homeostasis3

  • expert opinionα-MSH exerts immunomodulatory actions3

  • expert opinionFibrosis follows a path of activation or migration of fibroblasts and differentiation of fibroblasts to myofibroblasts which produce collagen and α-SMA3

  • expert opinionAlpha-melanocyte stimulatory hormone (α-MSH) is a melanocyte-stimulating hormone produced by the hypothalamus and released from the pituitary gland5

  • expert opinionα-MSH acts as an agonist to the melanocortin 5 receptor (MC5R) in human skeletal muscle5

  • expert opinionMC5R plays a role in glucose uptake and disposal5

  • expert opinionThe intermediate lobe of the pituitary is thought to be the primary source of alpha-melanocyte stimulating hormone (alpha-MSH)9

  • expert opinionα-MSH has potent protective and antiinflammatory effects12

  • expert opinionAlpha-melanocyte stimulating hormone (α-MSH) is a neuropeptide belonging to the melanocortin family16

  • expert opinionα-MSH is well known for its anti-inflammatory effects16

  • expert opinionα-MSH has antipyretic effects16

  • expert opinionα-MSH shares several characteristics with antimicrobial peptides (AMPs)16

  • expert opinionThe C-terminal residues of α-MSH exhibit antimicrobial activity parallel to that of the entire peptide16

  • expert opinionPOMC is a polypeptide hormone precursor expressed in the brain and in peripheral tissues such as the pituitary gland, immune system, and skin20

  • expert opinionIn the brain, POMC is processed to form several peptides including alpha-melanocyte stimulating hormone (α-MSH)20

  • expert opinionalpha-MSH is expressed in the hypothalamic arcuate nucleus and in the nucleus tractus solitarius of the brainstem20

  • expert opinionα-MSH has a crucial role in the regulation of metabolic functions20

  • expert opinionProduction and maturation processes of α-MSH have been shown to be regulated according to the metabolic condition of the organism20

  • theoreticalAlpha-MSH may be involved in neuronal maturation9

  • theoreticalAlpha-melanocyte stimulating hormone (α-MSH) and its receptor, melanocortin 1 receptor (MC1R), have tissue specific expression and involvement in melanocyte homeostasis14

  • theoreticalα-MSH is classified as a neuropeptide21

  • theoreticalα-MSH is derived from pro-opiomelanocortin (POMC) precursor protein21

  • theoreticalα-MSH is derived from the precursor protein pro-opiomelanocortin (POMC)21

Dosing

Based on 1 human trial finding and 1 expert opinion finding.

  • human trialSubcutaneous implants containing 16 mg of afamelanotide were administered every 60 days1

  • expert opinionPharmaceutical grade α-MSH will be dissolved in 0.9% saline containing 0.5% human albumin5

How the body handles it

Based on 1 human study finding, 1 animal finding and 1 expert opinion finding.

  • human studyThe plasma half-life of a-MSH is 20-25 min in humans11

  • animal[At]NpG-GGN4c showed tumor accumulation comparable to that of [I]NpG-GGN4b and maintained the tumor radioactivity retention from 1 to 3 h postinjection13

  • expert opinionthe biological half-life is unknown11

Safety and side effects

Based on 3 human trial findings, 4 human study findings and 1 expert opinion finding.

  • human trialAdverse events were mostly mild; serious adverse events were not thought to be related to the study drug1

  • human trialα-MSH analog was well tolerated and raised no safety concerns except for nonserious skin-related adverse events4

  • human trialAdverse events included headache, sexual-arousal disturbance, and penile issues4

  • human studyHe developed crops of new pigmented nevi, many of which had atypical clinical and histopathologic features8

  • human studyThe preexisting nevi became darker and acquired growth features8

  • human studySynthetic alpha-MSH peptides could present an increased risk for melanoma development in predisposed patients8

  • human studyNone of the patients showed any abnormalities in skin coloration9

  • expert opinionPharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia), approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA)5

What people use it for

Based on 3 human study findings, 8 expert opinion findings and 5 theoretical findings.

  • human studyMC5R is a potential target for cancer immunotherapy7

  • human studyA 40-year-old white man with a history of melanoma and multiple dysplastic nevi self-administered synthetic alpha-MSH8

  • human studyAbnormalities in the synthesis or release of alpha-MSH may be linked to the pathophysiology of Tourette's syndrome9

  • expert opinionMelanocortin agonists might have favorable effects in fibrosis3

  • expert opinionThis study seeks to investigate whether α-MSH can enhance glucose tolerance in patients with Type 2 Diabetes Mellitus5

  • expert opinionAlpha-melanocyte stimulating hormone (α-MSH) and its receptor, melanocortin 1 receptor (MC1R), have been proposed as potential target for anti-cancer strategies in melanoma research6

  • expert opinionTargeting MC1R could serve as an approach in the treatment of metastatic melanoma6

  • expert opinionSynthetic peptides that target proopiomelanocortin receptors are being investigated as a novel and safe way to tan8

Show 8 more findings

  • expert opinionMelanocortin-1 receptor (MC1R) is a promising target for radionuclide therapy of metastatic melanoma13

  • expert opinionα-MSH based peptides have prospects as a strong anti-infective agent16

  • expert opinionα-MSH is an anorexigenic peptide20

  • theoreticalTargeting MC1R could serve as an approach in the treatment of metastatic melanoma14

  • theoreticalα-MSH may be a potential therapeutic agent to stimulate bone formation for osteoporosis and bone defect15

  • theoreticalMC1R could be a target candidate for the treatment of bone metabolism diseases15

  • theoreticalAlpha-MSH peptide analogues are promising candidates for developing effective melanoma-specific imaging probes17

  • theoreticalRadiolabeled alpha-MSH peptide analogues can be used for melanoma imaging17

Other findings

Based on 5 theoretical findings.

  • theoreticalα-MSH is an endogenous peptide in human, mouse, or rat21

  • theoreticalα-MSH is also known as α-melanocyte stimulating hormone21

  • theoreticalα-MSH is an endogenous peptide found in human, mouse, and rat21

  • theoreticalα-MSH is classified as a neuropeptide21

  • theoreticalα-MSH is also known as α-melanocyte stimulating hormone21

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Reported plasma half-life of α-MSH varies across sources

Alpha-MSH: Research, Evidence, Dosing & Safety | Peptidings states a half-life of approximately 10 minutes and Alpha-MSH (Alpha-Melanocyte-Stimulating Hormone): Research Evidence & Safety Profile | PeptideInsight gives ~10-20 minutes in plasma, while THE ACTIONS OF THE a-MELANOCYTE STIMULATING ... reports a plasma half-life of 20-25 min in humans and notes the biological half-life is unknown.

Contested

α-MSH's role in melanoma is dual and contested (protective vs. tumor-promoting)

Some sources describe α-MSH as protective against melanoma development due to melanogenic activity and DNA damage repair (Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma | Journal of Translational Medicine | Springer Nature Link, Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma., alpha-Melanocyte-stimulating hormone-induced eruptive nevi.), while others report α-MSH/MC1R overexpression in metastatic melanoma, promotion of immune escape/therapy resistance, and tumor growth via MC5R (Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma | Journal of Translational Medicine | Springer Nature Link, Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression., Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma.), and a case report links self-administered synthetic α-MSH to atypical nevus proliferation and possible increased melanoma risk (alpha-Melanocyte-stimulating hormone-induced eruptive nevi.).

Limited evidence

Glucose/metabolic and diabetes benefits rest on preclinical and early-stage human work

Glucose clearance improvements come largely from mouse studies (Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes, Alpha-MSH) and limited healthy-human observations; the Type 2 Diabetes investigation (NCT06293664) is a very small crossover study (estimated enrollment 13) and results are not reported.

Single source

Elevated α-MSH in Tourette's syndrome is based on only three patients

The link between α-MSH and Tourette's syndrome/neurodevelopmental maturation comes from a single small study of 3 unmedicated patients and 3 controls (Alpha melanocyte stimulating hormone (MSH) in Tourette's syndrome.).

Single source

Osteogenic (bone formation) effects are in vitro only, from one source

The claim that α-MSH promotes osteoblast differentiation and mineralization and could treat osteoporosis derives from a single in vitro study in MC3T3-E1 cells (α-melanocyte stimulating hormone (α-MSH) promotes osteoblast differentiation of MC3T3-E1 cells.) and remains theoretical for therapeutic use.

Limited evidence

Several general mechanistic and pharmacological descriptions come from low-tier commercial/database sources

Detailed receptor Ki values, half-life, molecular weight, and broad functional summaries appear in tier 3/4 web and vendor sources (Alpha-MSH: Research, Evidence, Dosing & Safety | Peptidings, Alpha-MSH (Alpha-Melanocyte-Stimulating Hormone): Research Evidence & Safety Profile | PeptideInsight) and pharmacology databases (IUPHAR Guide to Pharmacology, α-MSH | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY) rather than primary clinical literature; these should be read as reference/theoretical characterizations.

Inconsistency

Afamelanotide 'every 60 days' contradicts the implant counts cited in the same trials

The profile states afamelanotide was given as 16 mg implants 'every 60 days,' but the cited trial parameters imply different intervals: US = 3 implants over 270 days (~90 days apart) and EU = 5 implants over 180 days (~36–45 days apart). Neither matches 60 days, so the stated frequency is internally inconsistent with the trial data attributed to Afamelanotide for Erythropoietic Protoporphyria.

What you may have heard

The receptor thought to carry α-MSH's effects on muscle glucose uptake and on tumor-related immune suppression is the one it binds most weakly, so those effects may appear only at…

α-MSH activates four melanocortin receptors, but its grip on MC5R (reported binding constant around 7,160 nM) is thousands of times weaker than its grip on MC1R (around 0.23 nM). Yet MC5R is the receptor credited with driving skeletal-muscle glucose disposal (the basis of an ongoing type 2 diabetes infusion study) and, in mice, with promoting the bone-marrow production of myeloid cells that suppress anti-tumor immunity. At the low concentrations of α-MSH normally present in the body, MC5R would be largely unoccupied, so these effects may be supraphysiologic — emerging only when α-MSH is infused or dosed at pharmacologic levels — rather than reflecting a normal endogenous mechanism.

What you may have heard

'improves glucose tolerance in healthy humans' / 'Research has demonstrated' rests on a study protocol, not reported res…

Claim 26 is graded human_observational but its source (Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes) is a trial protocol ('Protocol for Alpha MSH Infusion Study'), and the companion healthy-volunteer study (ISRCTN26265036) is described as ongoing. Asserting a demonstrated human benefit overstates what a protocol/registration can support.

Inconsistency

One source lists the pituitary as a source of α-MSH, another says the adult human pituitary contains none of it

The Peptidings profile lists the anterior pituitary (alongside the hypothalamus and UV-exposed keratinocytes) as a source of α-MSH, describing it as cleaved from POMC there. The study "Alpha melanocyte stimulating hormone (MSH) in Tourette's syndrome" states that the intermediate lobe of the pituitary is thought to be the primary source, that this lobe holds high concentrations in the human fetus, but that the human adult pituitary is devoid of the peptide. Read together, these leave the actual pituitary contribution in adults unclear, even though α-MSH is measurable in adult plasma.

Other

Admin routes conflate native-peptide research routes with analogue delivery

'Subcutaneous implant' applies to the engineered analogue afamelanotide, while IV saline/albumin is the native-peptide research route. Listing them together as α-MSH administration routes could imply the native peptide is delivered by implant, which the profile elsewhere says is not viable due to minutes-long half-life.

Using it with other compounds

Check a stack
  • OxytocinSame downstream effect

    Worth caution

    Both peptides act centrally to reduce food intake but through separate systems — alpha-MSH via hypothalamic MC4R signaling and oxytocin via oxytocin-receptor circuits interacting with the reward system. They converge on the same downstream output (satiety/appetite suppression), so effects on appetite may add together, which is worth monitoring.

    Tier 4Theoretical — not established
    What the research doesn't establish
    While alpha-MSH reduces appetite through well-documented MC4R signaling, oxytocin's characterized actions center on uterine contraction, milk ejection, and prosocial and reward-circuit effects; no pathway linking oxytocin to satiety or reduced food intake is established here. A shared appetite-suppressing output for the two peptides therefore rests on alpha-MSH alone and cannot be assumed for oxytocin.

    Shares appetite regulation

  • SemaglutideSame downstream effect

    Worth caution

    GLP-1 receptor activation reduces appetite in part by stimulating hypothalamic POMC neurons that release alpha-MSH acting on MC4R; alpha-MSH is that same downstream satiety signal. The two therefore hit overlapping appetite-suppression machinery, so effects on food intake may be additive but are mechanistically redundant.

    Tier 4Theoretical — not established
    What the research doesn't establish
    The claim that semaglutide suppresses appetite by driving hypothalamic POMC neurons to release alpha-MSH acting on MC4R is not established here: semaglutide's documented actions cover GLP-1 receptor agonism, insulin and glucagon effects, and PI3K/AKT signaling, with no reference to POMC neurons or alpha-MSH, and alpha-MSH's melanocortin signaling is not shown to be downstream of GLP-1. That the two act on a shared appetite pathway is assumed rather than demonstrated.

    Shares appetite regulation

  • Melanotan IISame mechanism

    Worth caution

    Melanotan II is a synthetic cyclic copy of alpha-MSH that activates the same melanocortin receptors (MC1R/MC3R/MC4R/MC5R) through the identical cAMP pathway, producing the same tanning and appetite-suppressing effects. Combining the two is redundant and simply compounds melanocortin overactivation (nausea, flushing, blood-pressure and libido effects) — choose one, don't layer them.

    Tier 3Largely anecdotal — commonly discussed

    Shares cAMP PKA · appetite regulation

  • BremelanotideSame mechanism

    Worth caution

    Alpha-MSH is the natural melanocortin hormone that bremelanotide was designed to mimic; both activate melanocortin receptors through the same cAMP/PKA cascade. Because bremelanotide is a targeted, longer-acting version of the same signal, adding alpha-MSH is largely redundant rather than complementary and would overlap on the same pathway.

    Tier 4Theoretical — not established

    Shares cAMP PKA

  • SemaxStack with caution

    Worth caution

    Semax is an ACTH(4-10) analog that is reported to act as an antagonist or partial agonist at melanocortin receptors. Because alpha-MSH is a full melanocortin agonist, Semax could partially oppose alpha-MSH's melanocortin-driven effects (pigmentation, appetite, central signaling) even though both share broad anti-inflammatory/NF-κB activity — worth understanding if you expect additive melanocortin action.

    Tier 4Theoretical — not established

    Shares anti inflammatory · NF kB modulation

  • LL-37Complementary

    Worth caution

    Both peptides fight microbes and modulate inflammation, but by different routes: alpha-MSH works through melanocortin receptors and NF-κB suppression, while LL-37 is a cationic cathelicidin that directly disrupts microbial membranes and signals through TLR/FPR2 pathways. Their distinct mechanisms converge on innate defense and tissue protection, so they are conceptually complementary rather than redundant.

    Tier 4Theoretical — not established

    Shares anti inflammatory · antimicrobial

  • ElafinComplementary

    Worth caution

    Elafin protects tissue by inhibiting neutrophil serine proteases and dampening NF-κB, whereas alpha-MSH suppresses inflammation through melanocortin/cAMP signaling and NF-κB. Both also carry antimicrobial activity. These are different upstream mechanisms landing on the same goal of resolving inflammation and protecting mucosal/tissue surfaces, making them a complementary pairing.

    Tier 4Theoretical — not established

    Shares anti inflammatory · antimicrobial · NF kB modulation

  • LactoferrinComplementary

    Worth caution

    Lactoferrin defends against microbes largely by sequestering iron and binding microbial surfaces, and calms inflammation via immune modulation — a completely different route from alpha-MSH's melanocortin/NF-κB-based antimicrobial and anti-inflammatory action. The two converge on innate immune defense through non-overlapping mechanisms, which is the hallmark of a complementary combination.

    Tier 4Theoretical — not established

    Shares anti inflammatory · antimicrobial

  • ThymulinComplementary

    No documented conflict

    Alpha-MSH suppresses NF-kB (preserving IkBα) and calms inflammatory cytokines through melanocortin receptors, a different upstream mechanism than thymulin's zinc-dependent immune regulation, but both converge on reduced inflammatory cytokine output.

    Tier 4Theoretical — not established

    Shares anti inflammatory · NF kB modulation

  • TirzepatideSame downstream effect

    Worth caution

    Alpha-MSH suppresses appetite by acting on hypothalamic melanocortin (MC4R) satiety circuits, while tirzepatide reduces appetite through hypothalamic GLP-1/GIP signaling — different upstream receptors that feed into the same central satiety output. The overlapping appetite-suppressing effect means the anorexigenic (and nausea) effects could compound.

    Tier 4Theoretical — not established

    Shares cAMP PKA

  • KPVSame mechanism

    Worth caution

    KPV is literally the C-terminal three-amino-acid tail (Lys-Pro-Val) of alpha-MSH and carries over the parent hormone's anti-inflammatory action — stabilising IκBα and suppressing NF-κB. In fact KPV was developed as the anti-inflammatory 'business end' of alpha-MSH without the pigmentation and appetite effects. Stacking the two for inflammation is largely redundant because they push the same NF-κB brake; alpha-MSH just adds melanocortin-receptor effects (tanning, appetite) that KPV was designed to avoid. Choose based on whether you want those extra effects, rather than combining for additive anti-inflammatory benefit.

    Tier 4Theoretical — not established

    Shares anti inflammatory · NF kB modulation

  • Palmitoyl Tetrapeptide-7Complementary

    No documented conflict

    Alpha-MSH is anti-inflammatory in skin via NF-κB suppression (IκBα preservation), and Palmitoyl Tetrapeptide-7 achieves an overlapping outcome by lowering IL-6/IL-1β secretion. They converge on reduced cutaneous inflammation through different mechanisms; note that alpha-MSH also strongly drives pigmentation, which the tetrapeptide does not, so effects beyond inflammation are not shared.

    Tier 4Theoretical — not established

    Shares anti inflammatory

  • CagrilintideSame downstream effect

    Worth caution

    Alpha-MSH suppresses appetite through melanocortin receptor (MC4R) signaling, a different upstream mechanism than cagrilintide's amylin pathway, but both feed into the same central satiety output. The overlap is conceptually additive, though alpha-MSH's broad pigmentary, immune and other effects make it a poor dedicated weight-loss pairing.

    Tier 4Theoretical — not established

    Shares appetite regulation

  • RetatrutideSame downstream effect

    Worth caution

    Alpha-MSH suppresses appetite centrally through hypothalamic MC4R signaling, converging on the same satiety/anorexigenic output that retatrutide produces via incretin/glucagon receptors. They are different upstream mechanisms feeding one downstream effect, so combining could amplify appetite suppression — potentially useful but also a reason to watch for excessive reduction in food intake.

    Tier 4Theoretical — not established

    Shares appetite regulation

  • AfamelanotideSame mechanism

    Worth caution

    Afamelanotide is a synthetic, longer-lasting analog of alpha-MSH and hits the exact same melanocortin-1 receptor (MC1R) through the same cAMP/PKA pigment-signaling cascade. Stacking them is redundant, not additive " you'd be activating the same receptor twice, and alpha-MSH's broader receptor spread (MC3R/MC4R/MC5R) just adds off-target effects (appetite, sexual) without improving the photoprotection or pigmentation goal. Choose one rather than combining.

    Tier 4Theoretical — not established

    Shares anti inflammatory · cAMP PKA

Safety and side effects

Safety and Tolerability

In the afamelanotide randomized controlled trials, adverse events were mostly mild and serious adverse events were not thought to be related to the study drug. In a separate clinical trial an α-MSH analog was well tolerated with no safety concerns except nonserious skin-related adverse events; reported adverse events included headache, sexual-arousal disturbance, and penile issues.

Melanoma / Pigmented Lesion Risk

A notable safety signal comes from a case report: a 40-year-old man with a history of melanoma and multiple dysplastic nevi who self-administered synthetic α-MSH developed crops of new pigmented nevi with atypical features and darkening/growth of preexisting nevi, which lightened and lost growth features after discontinuation. According to a case report, synthetic α-MSH peptides can drive proliferation of neoplastic melanocytic cells and could present an increased risk for melanoma development in predisposed patients, despite α-MSH being investigated as a tanning approach with proposed melanoma-protective effects. α-MSH's role in melanoma is genuinely dual and contested (protective vs. tumor-promoting).

Important Context

Much of the mechanistic and pharmacologic characterization (receptor Ki values, half-life, molecular data, broad functional summaries) comes from lower-tier database/commercial sources and should be read as reference/theoretical rather than clinical guidance. There is no evidence that the general population is broadly deficient in endogenous peptides, and injected therapeutic peptides are rarely in their exact natural form — most marketed products are heavily engineered analogs. Native α-MSH is metabolically unstable (degrading within minutes) and non-selective across receptors, which is why clinical development has favored engineered analogues.

Reconstitution and handling

Preparation and Administration

Pharmaceutical-grade α-MSH used in the referenced research is custom synthesized to GMP standards (by Auspep, Australia) and is administered dissolved in 0.9% saline containing 0.5% human albumin. The inclusion of albumin is consistent with a small, unstable peptide that carries the risk of surface adsorption and rapid degradation.

Analogue Dosing (for context)

The FDA-approved MC1R analogue afamelanotide was administered as subcutaneous implants containing 16 mg every 60 days in its erythropoietic protoporphyria trials. These implant regimens reflect the engineered analogues' improved stability rather than native α-MSH, which breaks down in minutes and activates too many receptors at once — a key reason it was not developed as a drug in its native form.

Practical Notes

  • Native α-MSH's very short plasma half-life (reported variously as ~10 minutes to 20–25 minutes) limits the utility of native-peptide dosing.
  • This section restates only what the cited research describes; it is not a dosing recommendation. Formulation, reconstitution vehicle, and dose in the literature (saline + 0.5% human albumin for native peptide; 16 mg 60-day implants for afamelanotide) are study-specific.

Sources

Ordered by evidence quality — the strongest first.

  1. Afamelanotide for Erythropoietic Protoporphyria(opens in a new tab)
    Tier 1Web · nejm.org
  2. Alpha-MSH(opens in a new tab)
    Tier 1Web · hra.nhs.uk
  3. Antifibrotic and Anti-Inflammatory Actions of α-Melanocytic Hormone: New Roles for an Old Player(opens in a new tab)
    Tier 1Web · mdpi.com
  4. Investigation of safety, tolerability, pharmacokinetics, and ...(opens in a new tab)
    Tier 1Web · pubmed.ncbi.nlm.nih.gov
  5. Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes(opens in a new tab)
    Tier 1Web · clinicaltrials.gov
  6. Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma | Journal of Translational Medicine | Springer Nature Link(opens in a new tab)
    Tier 1Web · link.springer.com · 2023
  7. Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  8. alpha-Melanocyte-stimulating hormone-induced eruptive nevi.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2009
  9. Alpha melanocyte stimulating hormone (MSH) in Tourette's syndrome.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1989
  10. Targeted Melanoma Imaging and Therapy with Radiolabeled Alpha ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  11. THE ACTIONS OF THE a-MELANOCYTE STIMULATING ...(opens in a new tab)
    Tier 2Web · dergipark.org.tr
  12. α-Melanocyte-Stimulating Hormone and Related Tripeptides(opens in a new tab)
    Tier 2Web · academic.oup.com
  13. AnAt-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  14. Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  15. α-melanocyte stimulating hormone (α-MSH) promotes osteoblast differentiation of MC3T3-E1 cells.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  16. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2014
  17. Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2007
  18. alpha-Melanocyte-stimulating hormone and oxytocin: a peptide signalling cascade in the hypothalamus.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2006
  19. The neuroimmunomodulatory peptide alpha-MSH.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2000
  20. Alpha-melanocyte stimulating hormone: production and degradation.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2010
  21. α-MSH | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY(opens in a new tab)
    Tier 4Web · guidetopharmacology.org

See something wrong or out of date on this page? Report it.